Posted by Michael Wonder on 16 Feb 2021
Sesen Bio announces FDA acceptance and priority review of its biologics license application for Vicineum
16 February 2021 - FDA stated it is not currently planning to hold an advisory committee meeting.
Sesen Bio announced today that the U.S. FDA accepted for filing the Company’s biologics license application for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer, and granted the application priority review.
